Daisy Alapat
Concepts (243)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 27 | 2024 | 3024 | 1.840 |
Why?
| Flow Cytometry | 5 | 2018 | 548 | 0.920 |
Why?
| Immunoglobulins | 2 | 2018 | 89 | 0.750 |
Why?
| Immunoglobulin kappa-Chains | 2 | 2016 | 31 | 0.680 |
Why?
| Bone Marrow | 7 | 2022 | 415 | 0.620 |
Why?
| DNA, Neoplasm | 1 | 2018 | 172 | 0.610 |
Why?
| Hematopoietic Stem Cell Transplantation | 4 | 2024 | 570 | 0.590 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2015 | 97 | 0.580 |
Why?
| Immunoglobulin lambda-Chains | 1 | 2015 | 18 | 0.540 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2016 | 70 | 0.540 |
Why?
| Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 6 | 0.530 |
Why?
| Receptors, Antigen, B-Cell | 1 | 2015 | 9 | 0.520 |
Why?
| Plasma Cells | 2 | 2016 | 238 | 0.490 |
Why?
| Neoplasm, Residual | 5 | 2022 | 167 | 0.470 |
Why?
| Plasmacytoma | 3 | 2022 | 47 | 0.430 |
Why?
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 13 | 0.420 |
Why?
| Lymphoma, Mantle-Cell | 1 | 2012 | 21 | 0.420 |
Why?
| Cell Differentiation | 1 | 2015 | 717 | 0.410 |
Why?
| Carcinoembryonic Antigen | 1 | 2011 | 15 | 0.400 |
Why?
| Calcitonin | 1 | 2011 | 40 | 0.390 |
Why?
| Antigens, CD | 1 | 2012 | 242 | 0.380 |
Why?
| Humans | 44 | 2024 | 54132 | 0.360 |
Why?
| Carcinoma | 1 | 2011 | 153 | 0.350 |
Why?
| Myogenin | 1 | 2008 | 6 | 0.340 |
Why?
| Muscle Fibers, Slow-Twitch | 1 | 2008 | 12 | 0.340 |
Why?
| Muscle Fibers, Fast-Twitch | 1 | 2008 | 14 | 0.340 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2022 | 108 | 0.340 |
Why?
| Paraproteinemias | 2 | 2022 | 79 | 0.320 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 1061 | 0.290 |
Why?
| Neoplasms, Second Primary | 2 | 2019 | 77 | 0.290 |
Why?
| Tumor Microenvironment | 3 | 2023 | 207 | 0.280 |
Why?
| Middle Aged | 16 | 2021 | 13094 | 0.270 |
Why?
| Prognosis | 7 | 2024 | 2116 | 0.260 |
Why?
| Gene Expression Profiling | 3 | 2016 | 1138 | 0.260 |
Why?
| Pancytopenia | 3 | 2016 | 40 | 0.250 |
Why?
| Treatment Outcome | 10 | 2022 | 5596 | 0.250 |
Why?
| Gastrointestinal Neoplasms | 1 | 2022 | 46 | 0.210 |
Why?
| Neoplasms, Plasma Cell | 2 | 2020 | 32 | 0.210 |
Why?
| Embolization, Therapeutic | 2 | 2021 | 98 | 0.210 |
Why?
| Thrombocytopenia | 1 | 2022 | 98 | 0.200 |
Why?
| Cryosurgery | 1 | 2021 | 38 | 0.200 |
Why?
| Chromosome Deletion | 2 | 2023 | 151 | 0.200 |
Why?
| Transplantation, Autologous | 4 | 2024 | 476 | 0.190 |
Why?
| Female | 18 | 2021 | 28437 | 0.190 |
Why?
| Skin Neoplasms | 2 | 2016 | 530 | 0.190 |
Why?
| Male | 15 | 2021 | 27350 | 0.180 |
Why?
| Aged | 14 | 2021 | 10059 | 0.180 |
Why?
| Combined Modality Therapy | 1 | 2021 | 694 | 0.170 |
Why?
| Ploidies | 1 | 2018 | 13 | 0.160 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2019 | 185 | 0.160 |
Why?
| Hematopoietic Stem Cells | 1 | 2019 | 215 | 0.160 |
Why?
| Herpesvirus 8, Human | 1 | 2019 | 89 | 0.160 |
Why?
| Sarcoma, Myeloid | 1 | 2017 | 22 | 0.150 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2017 | 43 | 0.150 |
Why?
| Kidney Diseases | 1 | 2020 | 292 | 0.150 |
Why?
| Immunohistochemistry | 3 | 2016 | 1097 | 0.150 |
Why?
| Lymph Nodes | 2 | 2019 | 282 | 0.150 |
Why?
| Amyloidosis | 2 | 2016 | 85 | 0.150 |
Why?
| CA-125 Antigen | 1 | 2016 | 20 | 0.150 |
Why?
| Cell Cycle | 1 | 2018 | 274 | 0.140 |
Why?
| Skin Diseases, Infectious | 1 | 2016 | 7 | 0.140 |
Why?
| Leukemia, Promyelocytic, Acute | 1 | 2016 | 10 | 0.140 |
Why?
| Anemia, Aplastic | 1 | 2016 | 12 | 0.140 |
Why?
| Myeloproliferative Disorders | 1 | 2016 | 28 | 0.140 |
Why?
| Electrophoresis, Capillary | 1 | 2015 | 16 | 0.140 |
Why?
| In Situ Hybridization | 1 | 2015 | 85 | 0.130 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2017 | 251 | 0.130 |
Why?
| V(D)J Recombination | 1 | 2015 | 4 | 0.130 |
Why?
| Immunophenotyping | 1 | 2015 | 117 | 0.130 |
Why?
| Fatal Outcome | 1 | 2015 | 225 | 0.130 |
Why?
| RNA, Messenger | 2 | 2015 | 1222 | 0.130 |
Why?
| Diagnosis, Differential | 3 | 2016 | 1133 | 0.130 |
Why?
| Bone Marrow Transplantation | 2 | 2022 | 149 | 0.120 |
Why?
| Immunoglobulin Light Chains | 1 | 2015 | 100 | 0.120 |
Why?
| Prealbumin | 1 | 2014 | 24 | 0.120 |
Why?
| Bone Marrow Neoplasms | 1 | 2014 | 15 | 0.120 |
Why?
| Neoplasm Proteins | 1 | 2016 | 367 | 0.120 |
Why?
| Hodgkin Disease | 1 | 2014 | 50 | 0.120 |
Why?
| Parvoviridae Infections | 1 | 2013 | 20 | 0.110 |
Why?
| Parvovirus B19, Human | 1 | 2013 | 17 | 0.110 |
Why?
| Polymerase Chain Reaction | 1 | 2015 | 533 | 0.110 |
Why?
| Partial Thromboplastin Time | 1 | 2012 | 12 | 0.110 |
Why?
| Prothrombin Time | 1 | 2012 | 19 | 0.110 |
Why?
| Immunoglobulins, Intravenous | 1 | 2013 | 55 | 0.110 |
Why?
| Afibrinogenemia | 1 | 2012 | 5 | 0.110 |
Why?
| Cardiomyopathies | 1 | 2014 | 128 | 0.110 |
Why?
| Retroperitoneal Neoplasms | 1 | 2012 | 17 | 0.110 |
Why?
| Glycoproteins | 1 | 2012 | 132 | 0.110 |
Why?
| Plasma Exchange | 1 | 2012 | 33 | 0.110 |
Why?
| Precursor Cells, B-Lymphoid | 1 | 2012 | 9 | 0.110 |
Why?
| Predictive Value of Tests | 1 | 2015 | 1053 | 0.110 |
Why?
| Phenotype | 1 | 2015 | 822 | 0.110 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 867 | 0.100 |
Why?
| Histoplasma | 1 | 2011 | 29 | 0.100 |
Why?
| Antigens, Fungal | 1 | 2011 | 31 | 0.100 |
Why?
| Immunoenzyme Techniques | 1 | 2011 | 165 | 0.100 |
Why?
| Hepatitis C | 1 | 2012 | 94 | 0.100 |
Why?
| Histoplasmosis | 1 | 2011 | 53 | 0.100 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2011 | 27 | 0.100 |
Why?
| In Situ Hybridization, Fluorescence | 3 | 2023 | 277 | 0.100 |
Why?
| Adult | 7 | 2021 | 14196 | 0.090 |
Why?
| Splenic Neoplasms | 1 | 2009 | 2 | 0.090 |
Why?
| Dose-Response Relationship, Drug | 2 | 2016 | 1478 | 0.090 |
Why?
| Disease Progression | 3 | 2022 | 915 | 0.090 |
Why?
| Myelodysplastic Syndromes | 1 | 2009 | 79 | 0.090 |
Why?
| Gene Expression | 1 | 2012 | 667 | 0.090 |
Why?
| Retrospective Studies | 4 | 2024 | 6387 | 0.080 |
Why?
| Mutagenesis, Site-Directed | 1 | 2008 | 117 | 0.080 |
Why?
| Thyroid Neoplasms | 1 | 2011 | 161 | 0.080 |
Why?
| Hemangioma | 1 | 2009 | 83 | 0.080 |
Why?
| HIV Infections | 1 | 2012 | 394 | 0.080 |
Why?
| Aged, 80 and over | 4 | 2019 | 3442 | 0.080 |
Why?
| Survival Analysis | 2 | 2021 | 739 | 0.080 |
Why?
| Protein Processing, Post-Translational | 1 | 2008 | 178 | 0.080 |
Why?
| Stem Cell Transplantation | 2 | 2022 | 196 | 0.070 |
Why?
| Cells, Cultured | 2 | 2008 | 1755 | 0.070 |
Why?
| Graft vs Host Disease | 1 | 2007 | 82 | 0.070 |
Why?
| Positron-Emission Tomography | 2 | 2021 | 323 | 0.070 |
Why?
| Muscle Proteins | 1 | 2008 | 308 | 0.070 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2005 | 37 | 0.070 |
Why?
| Semaphorin-3A | 1 | 2004 | 2 | 0.070 |
Why?
| Acid Anhydride Hydrolases | 1 | 2004 | 14 | 0.060 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 99 | 0.060 |
Why?
| Nerve Degeneration | 1 | 2004 | 33 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 56 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 57 | 0.060 |
Why?
| Muscle, Smooth, Vascular | 1 | 2005 | 144 | 0.060 |
Why?
| Ferritins | 1 | 2024 | 31 | 0.060 |
Why?
| Antineoplastic Agents | 1 | 2013 | 1295 | 0.060 |
Why?
| Imidazoles | 1 | 2005 | 143 | 0.060 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 19 | 0.060 |
Why?
| Pyridines | 1 | 2005 | 137 | 0.060 |
Why?
| Pyrimidines | 1 | 2005 | 196 | 0.060 |
Why?
| Gene Expression Regulation | 1 | 2008 | 1075 | 0.060 |
Why?
| Adrenal Cortex Hormones | 1 | 2023 | 96 | 0.060 |
Why?
| Hippocampus | 1 | 2004 | 240 | 0.060 |
Why?
| Chromosomes, Human, Pair 1 | 1 | 2023 | 113 | 0.050 |
Why?
| Enzyme Inhibitors | 1 | 2005 | 456 | 0.050 |
Why?
| Case-Control Studies | 2 | 2019 | 1242 | 0.050 |
Why?
| Cohort Studies | 2 | 2020 | 1549 | 0.050 |
Why?
| Mediastinum | 1 | 2021 | 27 | 0.050 |
Why?
| Dexamethasone | 1 | 2024 | 448 | 0.050 |
Why?
| Chromosome Aberrations | 1 | 2023 | 315 | 0.050 |
Why?
| Axilla | 1 | 2021 | 99 | 0.050 |
Why?
| Fever | 1 | 2022 | 129 | 0.050 |
Why?
| Vincristine | 1 | 2021 | 98 | 0.050 |
Why?
| Prednisone | 1 | 2021 | 111 | 0.050 |
Why?
| Pelvis | 1 | 2021 | 75 | 0.050 |
Why?
| Gastrointestinal Tract | 1 | 2022 | 135 | 0.050 |
Why?
| T-Lymphocytes | 1 | 2023 | 370 | 0.050 |
Why?
| Neurons | 1 | 2004 | 483 | 0.050 |
Why?
| Cyclophosphamide | 1 | 2021 | 171 | 0.050 |
Why?
| Signal Transduction | 2 | 2004 | 1754 | 0.050 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2021 | 205 | 0.050 |
Why?
| Radiopharmaceuticals | 1 | 2021 | 239 | 0.050 |
Why?
| Tumor Burden | 1 | 2020 | 142 | 0.050 |
Why?
| Alzheimer Disease | 1 | 2004 | 365 | 0.050 |
Why?
| Time Factors | 2 | 2017 | 3223 | 0.050 |
Why?
| Doxorubicin | 1 | 2021 | 258 | 0.040 |
Why?
| False Negative Reactions | 1 | 2019 | 35 | 0.040 |
Why?
| Herpesvirus 4, Human | 1 | 2019 | 38 | 0.040 |
Why?
| Epstein-Barr Virus Infections | 1 | 2019 | 34 | 0.040 |
Why?
| Registries | 1 | 2022 | 548 | 0.040 |
Why?
| Herpesviridae Infections | 1 | 2019 | 46 | 0.040 |
Why?
| Mice | 3 | 2023 | 6436 | 0.040 |
Why?
| Cell Line, Tumor | 1 | 2023 | 1542 | 0.040 |
Why?
| Virus Diseases | 1 | 2019 | 43 | 0.040 |
Why?
| Adolescent | 1 | 2011 | 6890 | 0.040 |
Why?
| Phosphorylation | 3 | 2005 | 609 | 0.040 |
Why?
| Antibodies, Monoclonal | 1 | 2023 | 560 | 0.040 |
Why?
| Genome, Viral | 1 | 2019 | 100 | 0.040 |
Why?
| DNA, Viral | 1 | 2019 | 142 | 0.040 |
Why?
| Follow-Up Studies | 1 | 2024 | 2384 | 0.040 |
Why?
| Tomography, X-Ray Computed | 2 | 2014 | 1210 | 0.040 |
Why?
| Neoplasm Recurrence, Local | 1 | 2022 | 643 | 0.040 |
Why?
| Scleromyxedema | 1 | 2016 | 5 | 0.040 |
Why?
| Schnitzler Syndrome | 1 | 2016 | 4 | 0.040 |
Why?
| Xanthomatosis | 1 | 2016 | 9 | 0.040 |
Why?
| Cryoglobulinemia | 1 | 2016 | 12 | 0.040 |
Why?
| Asymptomatic Diseases | 1 | 2016 | 43 | 0.030 |
Why?
| POEMS Syndrome | 1 | 2016 | 32 | 0.030 |
Why?
| Liver | 1 | 2022 | 1246 | 0.030 |
Why?
| Melphalan | 1 | 2016 | 181 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2016 | 488 | 0.030 |
Why?
| Reed-Sternberg Cells | 1 | 2014 | 2 | 0.030 |
Why?
| HIV Seronegativity | 1 | 2014 | 3 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 210 | 0.030 |
Why?
| Karyotype | 1 | 2014 | 19 | 0.030 |
Why?
| Animals | 3 | 2023 | 14435 | 0.030 |
Why?
| Fusion Proteins, bcr-abl | 1 | 2014 | 23 | 0.030 |
Why?
| Thalidomide | 1 | 2016 | 398 | 0.030 |
Why?
| Heterozygote | 1 | 2014 | 96 | 0.030 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 48 | 0.030 |
Why?
| Cell Division | 2 | 2005 | 330 | 0.030 |
Why?
| Remission Induction | 1 | 2014 | 222 | 0.030 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 682 | 0.030 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 473 | 0.030 |
Why?
| Fibrinogen | 1 | 2012 | 37 | 0.030 |
Why?
| Mutation | 1 | 2019 | 1499 | 0.030 |
Why?
| Blood Coagulation | 1 | 2012 | 70 | 0.030 |
Why?
| Survival Rate | 1 | 2015 | 955 | 0.030 |
Why?
| Neoplasm Staging | 1 | 2015 | 801 | 0.030 |
Why?
| Reference Values | 1 | 2012 | 356 | 0.030 |
Why?
| Risk Assessment | 1 | 2017 | 1363 | 0.030 |
Why?
| Antibodies, Fungal | 1 | 2011 | 4 | 0.030 |
Why?
| Mycological Typing Techniques | 1 | 2011 | 3 | 0.030 |
Why?
| Cross Reactions | 1 | 2011 | 58 | 0.030 |
Why?
| Lung Diseases, Fungal | 1 | 2011 | 31 | 0.030 |
Why?
| Biopsy | 1 | 2014 | 694 | 0.030 |
Why?
| Immunocompromised Host | 1 | 2011 | 130 | 0.020 |
Why?
| Splenectomy | 1 | 2009 | 35 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2012 | 1084 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2011 | 925 | 0.020 |
Why?
| Blood Transfusion | 1 | 2009 | 137 | 0.020 |
Why?
| Transplantation, Isogeneic | 1 | 2007 | 2 | 0.020 |
Why?
| Mice, Inbred C3H | 1 | 2007 | 81 | 0.020 |
Why?
| Laparoscopy | 1 | 2009 | 188 | 0.020 |
Why?
| Cyclosporine | 1 | 2007 | 66 | 0.020 |
Why?
| Mice, SCID | 1 | 2007 | 196 | 0.020 |
Why?
| Models, Animal | 1 | 2007 | 255 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2014 | 1603 | 0.020 |
Why?
| Immunosuppressive Agents | 1 | 2007 | 249 | 0.020 |
Why?
| Macromolecular Substances | 1 | 2004 | 47 | 0.020 |
Why?
| Physical Chromosome Mapping | 1 | 2004 | 10 | 0.020 |
Why?
| tau Proteins | 1 | 2004 | 29 | 0.020 |
Why?
| Genetic Complementation Test | 1 | 2004 | 55 | 0.020 |
Why?
| Epidermal Growth Factor | 1 | 2004 | 38 | 0.020 |
Why?
| Cricetulus | 1 | 2004 | 103 | 0.020 |
Why?
| Catalytic Domain | 1 | 2004 | 63 | 0.020 |
Why?
| Epitopes | 1 | 2004 | 88 | 0.020 |
Why?
| Microtubule-Associated Proteins | 1 | 2004 | 78 | 0.020 |
Why?
| Mutagenesis | 1 | 2004 | 77 | 0.020 |
Why?
| Cloning, Molecular | 1 | 2004 | 205 | 0.020 |
Why?
| Cricetinae | 1 | 2004 | 211 | 0.020 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 123 | 0.020 |
Why?
| Receptors, Cell Surface | 1 | 2004 | 133 | 0.020 |
Why?
| RNA | 1 | 2004 | 200 | 0.010 |
Why?
| Cell Survival | 1 | 2005 | 661 | 0.010 |
Why?
| Nerve Tissue Proteins | 1 | 2004 | 196 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 2004 | 777 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 2004 | 996 | 0.010 |
Why?
| Mice, Inbred C57BL | 1 | 2007 | 2021 | 0.010 |
Why?
| Cell Line | 1 | 2004 | 1166 | 0.010 |
Why?
|
|
Alapat's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|